WASHINGTON, July 7 (KUNA) -- The US government, on Tuesday, granted USD 1.6 billion to Novavax company to test and manufacture a possible COVID-19 vaccine by the end of 2020.
The biotechnology company said in a statement that it was chosen to participate in the US government's program, which aims to start providing millions of doses of safe and effective COVID-19 vaccine by 2021.
Novavax has been awarded USD 1.6 billion by the federal government to complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 million doses of its COVID-19 vaccine candidate, as early as late 2020, it added.
For his part, US Secretary of Health and Human Services Alex Azar said that "adding Novavax company to the group of various candidate vaccines providers within the government program increases the chances of getting a safe and effective vaccine by the end of this year". (end)